Research Article
BibTex RIS Cite

Evaluation of Drug-Drug Interactions in Renal Transplant Patients

Year 2023, Volume: 4 Issue: 3, 292 - 295, 29.11.2023

Abstract

Introduction: The number of patients with chronic renal failure is increasing day by day throughout the world and in our country. It is also known that these patients have increased mortality and morbidity. As a result, the rate of patients requiring renal replacement therapy is also increasing. Renal transplantation is the treatment method that offers the closest standard of living among renal replacement treatments, and it is also known that this group of patients uses many additional medications along with regular immunosuppressive treatment. In this study, we planned to investigate drug-drug interactions in renal transplant patients with multiple drug use.
Methods: Prescriptions of renal transplant patients who applied to the nephrology outpatient clinic between January and December 2022 were analyzed retrospectively.
Results: 94 prescriptions were included in the study. In the study, a total of 21 major, 34 medium, and 144 low-level interactions were detected in 94 prescriptions.
Conclusion: Drug-drug interactions are extremely common in kidney transplant patients. It is important for physicians and pharmacists who follow the patients to be aware of this situation and to question whether each new drug planned to be prescribed causes drug-drug interaction.

References

  • 1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385:1975-82.
  • 2. Böbrek Nakli Yıllara Göre İstatistik Sayfası. Türkiye Cumhuriyeti Sağlık Bakanlığı. Available at: https://organkds.saglik.gov.tr/DSS/PUBLIC/Transplant_ Kidney.aspx Accessed September 3, 2023.
  • 3. Andacoglu O, Aki FT. Global Perspective on Kidney Transplantation: Turkey. Kidney360. 2021; 2: 1160-62.
  • 4. Kidney transplantation in adults: Overview of care of the adult kidney transplant recipient. Available at: https://www.uptodate.com/contents/kidneytransplantation-in-adults-overview-of-care-of-the-adultkidney-transplant-recipient. Accessed September 3, 2023.
  • 5. National Institute of Diabetes and Digestive and Kidney Disease 2019 Annual Data Report. Available at: https://www.niddk.nih.gov/about-niddk/strategic-plansreports/usrds/prior-data-reports/2019. Accessed September 3, 2023.
  • 6. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019; 322: 1294-304.
  • 7. Marquito AB, Fernandes NMDS, Colugnati FAB, Paula RBD. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol. 2014; 36: 26-34.
  • 8. Shawahna R. Quality Indicators of Pharmaceutical Care for Integrative Healthcare: A Scoping Review of Indicators Developed Using the Delphi Technique. Evid Based Complement Alternat Med. 2020: 9131850.
  • 9. Bakker T, Klopotowska JE, de Keizer NF, et al. Improving medication safety in the Intensive Care by identifying relevant drug-drug interactions - Results of a multicenter Delphi study. J Crit Care. 2020; 57: 134-40.
  • 10. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006; 24: 704-12.
  • 11. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005; 56: 286- 90.
  • 12. Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM, Raees-Jalali GA. DrugDrug Interactions among Kidney Transplant Recipients in The Outpatient Setting. Int J Organ Transplant Med. 2020; 11: 185-95.
  • 13. Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 2009; 37: 821-6.
  • 14. Pascual J, del Castillo D, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation. 2010; 89: 994-1000.
  • 15. Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant 2012; 16: E217-20.
  • 16. Flothow DJG, Suwelack B, Pavenstädt H, SchütteNütgen K, Reuter S. The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients. J Clin Med. 2020; 9: 258.
  • 17. Zhao W, Baudouin V, Fakhoury M, Storme T, Deschênes G, Jacqz-Aigrain E. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. Transplantation. 2012; 93: e29-e30.
  • 18. Zuo XC, Zhou YN, Zhang BK, et al. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metab Pharmacokinet. 2013; 28:398-405.
  • 19. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins R. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother. 1997; 31: 571-5.
  • 20. Yang Y, Huang X, Shi Y, et al. CYP3A5 GenotypeDependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. Front Pharmacol. 2021;12:692922.

Renal Transplant Hastalarında İlaç-İlaç Etkileşimlerinin Değerlendirilmesi

Year 2023, Volume: 4 Issue: 3, 292 - 295, 29.11.2023

Abstract

Giriş: Dünya genelinde ve ülkemizde kronik böbrek yetmezlikli hasta sayısı her geçen gün artış göstermekte; bu hastaların artmış mortalite ve morbiditesinin olduğu da bilinmektedir. Bunun sonucu olarak renal replasman tedavisine ihtiyaç duyan hasta oranı da artmaktadır. Böbrek nakli renal replasman tedavileri içerisinde en normale yakın yaşam standardı sunan tedavi yöntemi olup bu grup hastanın düzenli immunsupresif tedaviyle birlikte pek çok ek ilaç kullanmakta olduğu da bilinmektedir. Bu çalışmada çoklu ilaç kullanımının olduğu renal transplantlı hastalardaki ilaç-ilaç etkileşimini araştırmayı planladık.
Yöntemler: Ocak - Aralık 2022 tarihleri arasında nefroloji polikliniğine başvuran renal transplant hastalarının reçeteleri geri dönük incelendi.
Bulgular: Çalışmaya 94 reçete dahil edildi. Araştırmada 94 reçetede toplam 21 majör, 34 orta ve 144 düşük seviyeli etkileşim tespit edildi.
Sonuç: Böbrek nakilli hastalarda ilaç-ilaç etkileşimi asımsanmayacak ölçüde sık görülmektedir. Bu durumun hastaları takip eden hekimler ve eczacılar tarafından bilinmesi ve yeni yazılması planlanan her ilacın ilaç-ilaç etkileşimine yol açıp açmadığının sorgulanması önem taşımaktadır.

References

  • 1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385:1975-82.
  • 2. Böbrek Nakli Yıllara Göre İstatistik Sayfası. Türkiye Cumhuriyeti Sağlık Bakanlığı. Available at: https://organkds.saglik.gov.tr/DSS/PUBLIC/Transplant_ Kidney.aspx Accessed September 3, 2023.
  • 3. Andacoglu O, Aki FT. Global Perspective on Kidney Transplantation: Turkey. Kidney360. 2021; 2: 1160-62.
  • 4. Kidney transplantation in adults: Overview of care of the adult kidney transplant recipient. Available at: https://www.uptodate.com/contents/kidneytransplantation-in-adults-overview-of-care-of-the-adultkidney-transplant-recipient. Accessed September 3, 2023.
  • 5. National Institute of Diabetes and Digestive and Kidney Disease 2019 Annual Data Report. Available at: https://www.niddk.nih.gov/about-niddk/strategic-plansreports/usrds/prior-data-reports/2019. Accessed September 3, 2023.
  • 6. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019; 322: 1294-304.
  • 7. Marquito AB, Fernandes NMDS, Colugnati FAB, Paula RBD. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol. 2014; 36: 26-34.
  • 8. Shawahna R. Quality Indicators of Pharmaceutical Care for Integrative Healthcare: A Scoping Review of Indicators Developed Using the Delphi Technique. Evid Based Complement Alternat Med. 2020: 9131850.
  • 9. Bakker T, Klopotowska JE, de Keizer NF, et al. Improving medication safety in the Intensive Care by identifying relevant drug-drug interactions - Results of a multicenter Delphi study. J Crit Care. 2020; 57: 134-40.
  • 10. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006; 24: 704-12.
  • 11. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005; 56: 286- 90.
  • 12. Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM, Raees-Jalali GA. DrugDrug Interactions among Kidney Transplant Recipients in The Outpatient Setting. Int J Organ Transplant Med. 2020; 11: 185-95.
  • 13. Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 2009; 37: 821-6.
  • 14. Pascual J, del Castillo D, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation. 2010; 89: 994-1000.
  • 15. Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant 2012; 16: E217-20.
  • 16. Flothow DJG, Suwelack B, Pavenstädt H, SchütteNütgen K, Reuter S. The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients. J Clin Med. 2020; 9: 258.
  • 17. Zhao W, Baudouin V, Fakhoury M, Storme T, Deschênes G, Jacqz-Aigrain E. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. Transplantation. 2012; 93: e29-e30.
  • 18. Zuo XC, Zhou YN, Zhang BK, et al. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metab Pharmacokinet. 2013; 28:398-405.
  • 19. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins R. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother. 1997; 31: 571-5.
  • 20. Yang Y, Huang X, Shi Y, et al. CYP3A5 GenotypeDependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. Front Pharmacol. 2021;12:692922.
There are 20 citations in total.

Details

Primary Language English
Subjects Nefroloji, Clinical Sciences (Other)
Journal Section Research Articles
Authors

Rüya Mutluay 0000-0002-7159-0082

Sinem Gürcü 0000-0001-8534-7369

Publication Date November 29, 2023
Submission Date November 2, 2023
Acceptance Date November 14, 2023
Published in Issue Year 2023 Volume: 4 Issue: 3

Cite

APA Mutluay, R., & Gürcü, S. (2023). Evaluation of Drug-Drug Interactions in Renal Transplant Patients. Eskisehir Medical Journal, 4(3), 292-295.
AMA Mutluay R, Gürcü S. Evaluation of Drug-Drug Interactions in Renal Transplant Patients. Eskisehir Med J. November 2023;4(3):292-295.
Chicago Mutluay, Rüya, and Sinem Gürcü. “Evaluation of Drug-Drug Interactions in Renal Transplant Patients”. Eskisehir Medical Journal 4, no. 3 (November 2023): 292-95.
EndNote Mutluay R, Gürcü S (November 1, 2023) Evaluation of Drug-Drug Interactions in Renal Transplant Patients. Eskisehir Medical Journal 4 3 292–295.
IEEE R. Mutluay and S. Gürcü, “Evaluation of Drug-Drug Interactions in Renal Transplant Patients”, Eskisehir Med J, vol. 4, no. 3, pp. 292–295, 2023.
ISNAD Mutluay, Rüya - Gürcü, Sinem. “Evaluation of Drug-Drug Interactions in Renal Transplant Patients”. Eskisehir Medical Journal 4/3 (November 2023), 292-295.
JAMA Mutluay R, Gürcü S. Evaluation of Drug-Drug Interactions in Renal Transplant Patients. Eskisehir Med J. 2023;4:292–295.
MLA Mutluay, Rüya and Sinem Gürcü. “Evaluation of Drug-Drug Interactions in Renal Transplant Patients”. Eskisehir Medical Journal, vol. 4, no. 3, 2023, pp. 292-5.
Vancouver Mutluay R, Gürcü S. Evaluation of Drug-Drug Interactions in Renal Transplant Patients. Eskisehir Med J. 2023;4(3):292-5.